REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc.

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Replimune Group, Inc. (NASDAQ: REPL) securities during the specified period, alleging that the company misled investors regarding the viability of its IGNYTE trial [1][2]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that Replimune Group, Inc. failed to disclose significant issues regarding the IGNYTE trial, which led to the FDA deeming the trial inadequate and not well-controlled [2]. - It is alleged that the defendants overstated the prospects of the IGNYTE trial, resulting in materially false and misleading statements about Replimune's business and operations [2]. - Following the announcement of a complete response letter (CRL) from the FDA on July 22, 2025, which indicated that the IGNYTE trial did not provide substantial evidence of effectiveness, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.80 per share [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by September 22, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for cancer treatment [1]. - Robbins LLP has been recognized for its efforts in shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].